Trials / Unknown
UnknownNCT02944812
Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma
Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma, a Single-Center, Nonrandomized Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial intends: 1.To evaluate the concentration of Chidamide in the serum and cerebral-spinal fluid of PTCL patients at certain time points after taking the medicine, to evaluate the pharmacokinetics of Chidamide in these patients and its CNS (central nervous system) distribution. 2\. To evaluate the efficiency and safety of Chidamide in PTCL patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained. |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2016-10-26
- Last updated
- 2016-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02944812. Inclusion in this directory is not an endorsement.